Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)?
Coker
Richard
R
Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, UK.
D000995:Antitubercular Agents / Q000627:therapeutic use*; D003140:Communicable Disease Control / Q000191:economics; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D006801:Humans; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*
D000995:Antitubercular Agents